Market Overview

The Week Ahead In Biotech: Conferences, Clinical Trials

The Week Ahead In Biotech: Conferences, Clinical Trials

The new year kick started with a bumper deal in the pharma space, with Bristol-Myers Squibb Co (NYSE: BMY) agreeing to buy Celgene Corporation (NASDAQ: CELG).

Can the deal infuse some momentum into the space following a down year? Here are some key catalysts of the upcoming week that could provide an answer.

Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here


  • 6th Annual Dermatology Summit - Jan. 6, in San Francisco, California
  • Biotech Showcase – Jan. 7-9, in San Francisco
  • 37th Annual JPMorgan Healthcare Conference – Jan.7-10, in San Francisco
  • 11th Annual T-cell Lymphoma Forum – Jan. 10-12, in La Jolla, California

Clinical Trials

Axsome Therapeutics Inc (NASDAQ: AXSM) is due to release Phase 2 data for AXS-05 which is being evaluated in a study dubbed ASCEND for treating major depressive disorder. The release is scheduled for early January.

Miragen Therapeutics Inc (NASDAQ: MGEN) will present updated Phase 1 data for Cobomarsen at the 11th annual T-cell Lymphoma Forum at 6 pm PT Jan. 11. Cobomarsen is being evaluated for a variety of blood cancer types such as chronic lymphocytic leukemia, diffuse large B-cell lymphoma and cutaneous T-cell lymphoma.

IPO Quiet Period Expiry

Hong Kong-based pharma company Aptorum Group Ltd (NASDAQ: APM) offered 1.9 million shares in an IPO in December, with the offering priced at $15.80. The shares were listed on the Nasdaq Dec. 18 and closed the debut session at $14.35.
Related Links:

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Morgan Stanley: Moderna Has Significant Competitive Advantage

Posted-In: Biotech News Previews IPOs Trading Ideas Best of Benzinga


Related Articles (AXSM + APM)

View Comments and Join the Discussion!

Benzinga's Bulls & Bears Of The Week: Amazon, CBS, Intel, Nike, Tesla And More

Barron's Picks And Pans: Apple, Exxon, Morgan Stanley And More